Research Opportunities
We want to help kidney cancer researchers locate funding opportunities. We’ll update this page with grant opportunities as we learn about them. Know of one we haven’t listed? Email us at [email protected], or tweet at us, and we’ll get it posted!
KidneyCAN is dedicated to accelerating kidney cancer research.
Our advocacy for the DoD Kidney Cancer Research Program resulted in appropriations of $50 million in fiscal year 2022 for kidney cancer research, bring the 2017-2022 total to $185 million. In 2016, this number was $0.
Our Kidney Cancer Research Summit brings translational researchers in kidney cancer together in an annual collaborative meeting.
Additionally, KidneyCAN’s “Rock the Cure” events have raised over $1,000,000 toward private research support.
Please share this notice with other researchers in your network.
- Develop your ideas
- Build your team – even including members from other institutions
- Gather letters of support
- Review the grant mechanisms (including the new ones) and consider which would best support your idea
- Consider partnerships (including industry partnerships) and collaborations
FY21 KCRP Program Announcements Released
As new announcements are posted, we will keep you updated.
AACR: New Funding Opportunities
We’d love to see more RCC applicants for these prestigious grant opportunities.
KidneyCAN is proud to present the 4th annual Kidney Cancer Research Summit on October 6-7, 2022. KCRS is a meeting focused on basic, translational, and clinical kidney cancer research. This meeting is fueled by the ideas and research funded through the Department of Defense CDMRP-KCRP awards.
The goal for KCRS is to present the important, innovative research funded by the KCRP. We also aim to connect researchers from around the world to share their work.
Kidney cancer is the ideal sandbox for these new approaches, and without a doubt the same approach can, should and will be suitable for other cancers.
Dr. Hans Hammers, UTSW
RESEARCH UPDATES
District Days: Asking Congress to Fund Kidney Cancer Research
On August 8-9th, KidneyCAN gathered advocates from all over the United States to ask Congress for robust funding for kidney cancer research through the NIH and CDMRP (Congressionally Directed Medical Research Programs). Read on to hear about our goals for this event...
Dr. Brandon Manley: Physician, Scientist, Advocate
Brandon Manley, M.D., is a urologic oncologist who specializes in genitourinary oncology, with a focus on patients with kidney cancer. He currently practices at Moffitt Cancer Center in Tampa, Florida, where he lives with his wife Aimee, and his two daughters Sadie...
IKCC Report: Retention in Clinical Trials
The International Kidney Cancer Coalition launched a pilot program to understand the barriers and other considerations that drive the decision to leave a clinical trial and uncover ways to better support patients currently in or considering joining clinical trials....
Join Our Grassroots Army
;
Gmorning! Start your day by checking something easy off your list: REGISTER for #KCRS22!
We are 2 weeks out, and you do not want to miss this meeting! We've gathered some of the biggest names in #kidneycancer #RCC #research.
Grab your virtual seat here: https://kcrs.kidneycan.org/
Excited to share the official news that I will be spending the next five(!) years studying #kidneycancer . Grateful to my mentors and advisors for their continuous support and motivation!
This is wonderful! Congratulations, Debbie, and @KidneyCancer_Ca 🧡💚
Debbie’s #MOVEtobeatcancer started a little earlier doing something just for her. For her 1st year #kidneycancer free anniversary, she got a bee tattoo. Today for her 5th year anniversary, she added the @KidneyCancer_Ca symbol. So cool! View Debbie’s MOVE: https://bit.ly/3qRRRQY
Just in @oncogenejournal by our faculty: ISCA2 inhibition👉inhibits HIF & induce ferroptosis in VHL-null RCC @KidneyCancer .KD025, an oral ISCA2 inhibitor –a new path forward for ccRCC👉 http://rdcu.be/cVpP2 @mykoh1 @neerajaiims @oncoalert @kidneycan @huntsmancancer @IKCCorg
So very sorry to hear of Gary’s passing. Sincere condolences to Susan and family. 💚 @KidneyCancer_Ca @CancerduRein https://twitter.com/kidneycan/status/1570468564477546496
The KidneyCAN team is deeply saddened to share the loss of Gary Poteat, beloved husband of Susan. Many of you know Susan as our Medical Science Liaison.
Please read about Gary's extraordinary life and join us in offering condolences to the family.
https://kidneycan.org/gary-poteat-in-memory/
Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on RCC: Review of Two Key Abstracts on Belzutifan Plus Cabozantinib and Pembrolizumab Plus Lenvatinib https://ascopost.com/videos/esmo-congress-2022/rcc-review-of-two-key-abstracts-on-belzutifan-plus-cabozantinib-and-pembrolizumab-plus-lenvatinib/ #ESMO22 #kcsm #kidneycancer #RCC @DanaFarber @DrChoueiri @HarvardMed @GustaveRoussy @AlbigesL
Hear the latest in kidney cancer care, emerging therapies and general wellness from Sandy Liu, MD of @cityofhope and a panel of experts at CURE®’s Educated Patient® Kidney Cancer Summit on Saturday, October 15.
@crisbergerot @IKCCorg @EJonasch @tompowles1 @AlbigesL @DrDanielHeng @DrCraigGedye @MichaelASJewett @BettinaRyll @MiekeVHR @jangeissler @filicevas @RachelGiles6 Agree @crisbergerot. What an innovative exchange of ideas between advocates, researchers, clinician leaders. Looking fwd to seeing those sparks develop into action plans for global #kidneycancer advocacy
Delighted to be @IKCCorg Clinical Leadership Workshop
Fantastic meeting
Thank you @EJonasch 4 this special invitation
Lovely to see/talk @tompowles1 @AlbigesL @DrDanielHeng @DrCraigGedye @DebMaskens @MichaelASJewett @BettinaRyll @MiekeVHR @jangeissler @filicevas @RachelGiles6
The KidneyCAN team is deeply saddened to share the loss of Gary Poteat, beloved husband of Susan. Many of you know Susan as our Medical Science Liaison.
Please read about Gary's extraordinary life and join us in offering condolences to the family.
https://kidneycan.org/gary-poteat-in-memory/
